CEU 2019 Session Recordings
CEU 2019 Session Recordings
Keep your endocrine practice up-to-date with Clinical Endocrinology Update (CEU) Session Recordings. This activity provides the latest information available in clinical endocrinology. Taught by expert faculty in a dynamic meeting format, you will finish viewing the CEU Session Recordings confident that your endocrine practice benefits from the most current and advanced information possible. Purchase access to the CEU 2019 Session Recordings today!
To purchase access to the CEU 2019 Session Recordings activity, visit the Endocrine Society Online Store by clicking the button below.
Access the latest clinical endocrine updates
Earn AMA PRA Category 1 Credits™
Download mp3 audio files to listen on the go
Upon completion of this educational activity, learners will be better able to:
- Discuss state-of-the-art research in endocrinology
- Demonstrate updated knowledge of the pathophysiology, diagnosis, and treatment of diabetes, obesity, cardiovascular disease, dyslipidemia, as well as adrenal, metabolic, bone, pediatric, pituitary, thyroid, and reproductive endocrine disorders
- Employ enhanced skills and practice management techniques to improve patient care
|Category||Session Title||Featured Speaker||Session Duration|
|Adrenal||Adrenal Cushing Diagnosis and Management||Lynette K. Nieman MD||0:45|
|Adrenal||Adrenal Incidentaloma: Challenging Cases||William F. Young Jr. MD||0:45|
|Adrenal||Challenges of Managing Paraganglioma and Pheochromocytoma||Anand Vaidya MD MMSC||0:30|
|Adrenal||Adrenal Questions and Answers||Lynette K. Nieman MD||0:30|
|Adrenal||Diagnosis and Management of Adrenal Insufficiency||William F. Young Jr. MD||0:30|
|Adrenal||Q&A/Panel Discussion||Anand Vaidya MD MMSC, Lynette K. Nieman MD, William F. Young Jr. MD||0:20|
|Calcium and Bone||Drug Holidays: What patients and what drugs?||E. Michael Lewiecki MD||0:30|
|Calcium and Bone||Fracture Healing||Nelson B. Watts MD||0:30|
|Calcium and Bone||Premenopausal Osteoporosis||Adi Cohen MD||0:30|
|Calcium and Bone||From T to Z: The Basics of Bone Density Interpretation||Micol Rothman MD||0:20|
|Calcium and Bone||Q&A/Panel Discussion||E. Michael Lewiecki MD, Nelson B. Watts MD, Adi Cohen MD, Ejigayehu G. Abate MD||0:15|
|Calcium and Bone||Overview of Rare Bone Disease||E. Michael Lewiecki MD||0:45|
|Diabetes||Diabetes on a Budget||David Matthew Nathan MD||0:40|
|Diabetes||Contemporary Management of T1D in Pregnancy||Carol J. Levy MD CDE||0:30|
|Diabetes||Update on Diabetic Nephropathy||Robert C. Stanton MD||0:30|
|Diabetes||Q&A/Panel Discussion||David Matthew Nathan MD, Carol J. Levy MD CDE, Robert C. Stanton MD||0:15|
|Diabetes||Glycemic Management after Bariatric Surgery||Mary-Elizabeth Patti MD||0:30|
|Diabetes||Safety of Novel Agents in T2D Management||Carol Wysham MD||0:30|
|Diabetes||Challenges with Technology: Difficult Pump and CGM Cases||Anders L. Carlson MD||0:30|
|Diabetes||Q&A/Panel Discussion||Mary-Elizabeth Patti MD, Carol Wysham MD, Anders L. Carlson MD||0:20|
|Diabetes||Treatment of Diabetes in the Elderly||Mark E. Molitch MD||0:45|
|Diabetes||Revisiting Old Drugs for T2D||David Matthew Nathan MD||0:45|
|Diabetes||Challenges in the Evaluation and Management of Hypoglycemia||Mary-Elizabeth Patti MD||0:45|
|Female Reproduction||HRT for Women||Margaret E. Wierman MD||0:45|
|Female Reproduction||PCOS Treatment||Anuja Dokras MD PhD||0:30|
|Female Reproduction||Controversies in the Treatment of Women with Menopausal Hormones||Anuja Dokras MD PhD, Cynthia A. Stuenkel MD, Margaret E. Wierman MD||0:30|
|Female Reproduction||Q&A/Panel Discussion||Anuja Dokras MD PhD, Cynthia A. Stuenkel MD, Margaret E. Wierman MD||0:15|
|Male Reproduction||When Not to Use Testosterone in Men||Shehzad S. Basaria MD||0:45|
|Male Reproduction||Hypogonadal Cases||Frances J. Hayes MBBCh BAO||0:30|
|Male Reproduction||Testosterone Replacement Modalities: Pros, Cons and their Correct Use||Shehzad S. Basaria MD||0:30|
|Male Reproduction||Q&A/Panel Discussion||Frances J. Hayes MBBCh BAO, Shehzad S. Basaria MD||0:15|
|Neuroendocrine and Pituitary||Cushing's Disease: Update on Treatment||Maria Fleseriu MD||0:30|
|Neuroendocrine and Pituitary||Non-Functioning Pituitary Adenomas||Shlomo Melmed MB ChB||0:30|
|Neuroendocrine and Pituitary||Prolactinomas: Special Topics||Mark E. Molitch MD||0:30|
|Neuroendocrine and Pituitary||Q&A/Panel Discussion||Maria Fleseriu MD, Shlomo Melmed MB ChB, Mark E. Molitch MD||0:15|
|Neuroendocrine and Pituitary||Hypophysitis: Etiology and Management||Maria Fleseriu MD||0:45|
|Neuroendocrine and Pituitary||Diagnosis and Management of Hyponatremia||Joseph G. Verbalis MD||0:45|
|Obesity||Helping Patients Find Motivation for Lifestyle Change||Scott Kahan MD MPH||0:30|
|Obesity||What’s New in Obesity Treatment?||Donna H. Ryan MD||0:30|
|Obesity||The New Cholesterol Management Guidelines||Lisa R. Tannock MD||0:30|
|Obesity||Q&A/Panel Discussion||Scott Kahan MD MPH, Donna H. Ryan MD, Lisa R. Tannock MD||0:15|
|Obesity||Pharmacotherapy for Weight Reduction||Donna H. Ryan MD||0:45|
|Obesity||Challenging Cases in Lipid Management||Lisa R. Tannock MD||0:45|
|Thyroid||Grave’s Orbitopathy||George J. Kahaly MD PhD||0:45|
|Thyroid||Treatment Options for Advanced Thyroid Cancer||Stephanie Fish MD||0:45|
|Thyroid||Molecular Markers in the Workup of Thyroid Nodules||Matthew D. Ringel MD MSc||0:45|
|Thyroid||Risk Stratification in Thyroid Cancer||Stephanie Fish MD||0:30|
|Thyroid||Diagnosis and Management of Graves’ Hyperthyroidism||George J. Kahaly MD PhD||0:30|
|Thyroid||Q&A/Panel Discussion||Stephanie Fish MD; George J. Kahaly MD PhD||0:15|
|Thyroid||Clinical Update on Thyroid and Pregnancy||Elizabeth N. Pearce MD MSc||0:30|
|Thyroid||Unusual Thyroid Function Tests: Cases to Panelists||Stephanie Fish MD, George J. Kahaly MD PhD, Elizabeth N. Pearce MD MSc||0:45|
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to The Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:
Anders Carlson, MD has had his institution receive remuneration for consulting and/or clinical research from Novo Nordisk, Sanofi, Medtronic, Dexcom, Abbott, Eli Lilly, and Insulet.
Adi Cohen, MD has received research support from Eli Lilly and Amgen.
Maria Fleseriu, MD has received scientific consulting fees from Novarits and Strongbridge; and has had her institution receive research support from Novartis, Millendo, and Strongbridge
George J. Kahaly, MD, PhD has served as a consultant to Quidel USA; and has had his institution receive a research grant from Quidel.
E. Micheal Lewiecki, MD has had his employer receive research grants from Radius, Amgen, Mereo, and Bindex; has received income for service on scientific advisory board or consulting from AMgen, Radius, Alexion, Sandoz, Samsung, and Bioepis; has served on speakers bureaus for Radius, Alexion; has worked on project development for University of New Mexico; has received royalties from UpToDate sections; and has served as a board member for the National Osteoporosis Foundation, International Society for Clinical Densitometry, and Osteoporosis Foundation of New Mexico.
Mark E. Molitch, MD has served as a consultant to Merck, Pfizer, Novartis, Chiasma, Corcept and Janssen; and has worked as a primary investigator for Janssen, Novartis, and Bayer.
David M. Nathan, MD has received research support from Alere, Inc (now Abbott).
Mary-Elizabeth Patti, MD has served as a collaborator for NIH R44 grant funded by Xeris Pharmaceuticals; has worked as a consultant for Fractyl and Eiger Pharmaceuticals; and has received investigator-initiated research support to her institution from Xeris Pharmaceuticals and Dexcom.
Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.
Donna H. Ryan, MD has received consulting fees from Amgen, Bausch Health, Boeringer Ingelheim, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, and Scientific Intake; has served on the speakers bureau for Novo Nordisk; has an ownership interest in Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake; and has served on the SELECT Steering Committee for Novo Nordisk.
Joseph G. Verbalis, MD has received consulting fees from Ferring Pharmaceuticals; and has received research support from Corcept Therapeutics.
Nelson B. Watts, MD has served as a consultant for Abbvie, Amgen, and Sanofi; and served as a speaker for Amgen and Radius.
Carol Wysham, MD has served as a consultant to Astra Zeneca, Abbott, Janssen, Novo Nordisk, and Sanaofi; has been in the speakers bureau for Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi; and has received research funding from Abbott, Novo Nordisk and Mylan.
The following faculty report no relevant financial relationships: Shehzad S. Basaria, MD; Anuja Dokras, MD, PhD; Stephanie Fish, MD; Scott Kahan, MD, MPH; Carol J. Levy, MD, CDE; Shlomo Melmed, MD; Lynnette K. Nieman, MD; Elizabeth N. Pearce, MD, MSc; Matthew D. Ringel, MD; Robert C. Stanton, MD; Lisa R. Tannock, MD; Anand Vaidya, MD, MMSc; Margaret E. Wierman, MD; William F. Young, Jr, MD, MSc.
Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.
USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
The Endocrine Society is proud to partner with industry to advance excellence and promote scientific discovery, medical practice and human health.:
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this enduring activity for a maximum of 28.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Use the links in the table below to go to the CEU Topical Courses to start the activities. Click the button below the table to visit the Endocrine Society store for purchase options.